| Document |
Document Title |
|
WO/2015/023170A1 |
A method for the preparation N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- quinazolin-4-amine (erlotinib) from 6,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one and 3-aminophenylacetylene in the presence of titanium(IV) chloride and anisole i...
|
|
WO/2015/019121A1 |
The present invention relates to styryl quinazoline derivatives of the general formula (I) and pharmaceutically acceptable solvates, hydrates, salts, regioisomeric and polymorphic forms thereof as well as pharmaceutical compositions cont...
|
|
WO/2015/014900A1 |
The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with th...
|
|
WO/2015/014230A1 |
The present invention relates to a matrix metalloproteinase inhibitor and a use thereof. In particular, the matrix metalloproteinase inhibitor has a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, and can...
|
|
WO/2015/014733A1 |
Compounds of formula (I) wherein the other substituents HetAr, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in claim 1, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly ...
|
|
WO/2015/010533A1 |
Disclosed are a fluorine pyribenzoxim compound with herbicidal activity and a preparation method therefor. The fluorine pyribenzoxim compound is O-[2,6-bis(4,6-dimethoxy-2-pyrimidinyl)oxygroup]benzoylpheny
l(2-trifluoromethyl) formaldoxi...
|
|
WO/2015/007219A1 |
Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.
|
|
WO/2015/008294A1 |
The present invention relates to process for the preparation of 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfon
ylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid calcium having formula (I). The compound of formu...
|
|
WO/2015/008073A1 |
The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychi...
|
|
WO/2015/003441A1 |
The present invention belongs to the technical field of organic electroluminescent materials, and provides a 9,10-bis[2-(p-substituted phenyl)pyrimidin-4-yl]anthracene compound and a preparation method thereof, an organic electroluminesc...
|
|
WO/2015/004028A1 |
The present application relates to new heterocyclic compounds of formula (I), wherein D stands for a substructure of formula (I-A), a method for the production thereof and the use thereof for combatting animal pests, including arthropods...
|
|
WO/2015/003951A1 |
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
|
|
WO/2015/003879A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, are useful as a pesticides.
|
|
WO/2015/006591A1 |
Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or -C(R1)(R2)(R3)...
|
|
WO/2015/003658A1 |
Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate...
|
|
WO/2015/004265A1 |
The present invention relates to a process for preparing a pyrimidine intermediate, namely the compound of formula I-2 or a salt thereof. Said compound of formula I-2 or its salt can be used to prepare macitentan. Macitentan (chemical na...
|
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2015/001572A2 |
The present invention provides a novel processes for preparation of methyl 3- (benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-l-(2-oxoet
hyl)-l,4-dihydropyiridine-2- carboxylate using novel intermediates.
|
|
WO/2015/003095A1 |
The invention provides sunless tanning compositions comprising a compounds of formula (I): or a salt thereof as described herein as well as methods for tanning mammalian skin by contacting the skin with the compounds of formula (I) or co...
|
|
WO/2014/151871A9 |
Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): [FORMULA SHOULD BE INSERTED HERE] including stereoisomers, tautomers, pharmaceutically acceptable sa...
|
|
WO/2014/206922A1 |
This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1 a or MNK1 b) and/or MNK2 (MNK2a or MNK2b) kina...
|
|
WO/2014/203176A1 |
Provided is water-soluble hair growth compositions for treating alopecia and stimulating hair regrowth, comprising a hair growth stimulant and a multifunctional compound, preferably L-oxothiazolidine-4-carboxylic acid.
|
|
WO/2014/205234A1 |
The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfun...
|
|
WO/2014/203044A1 |
The invention relates to novel dihydropyrimidin-2(lH)-ones and dihydropyrimidin- 2(lH)-thiones of formula (la). The invention also relates to the use of such compounds as medicaments, and in particular as inhibitors of sodium iodide symp...
|
|
WO/2014/202994A1 |
The invention provides a new bioorthogonal deprotection method for preparing heterocyclic compounds by bond cleavage using palladium. The methods have general application in the field of biological synthetic chemistry. Compounds, such as...
|
|
WO/2014/202737A1 |
The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when iso...
|
|
WO/2014/202703A1 |
The present invention relates to novel strobilurine type compounds I, processes for preparing these compounds, a use of compounds of the formula I and/or their agriculturally useful salts for controlling phytopathogenic fungi, to composi...
|
|
WO/2014/205223A1 |
Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic ...
|
|
WO/2014/198178A1 |
The present invention relates to a new crystalline form of macitentan. The new crystalline form has advantages in terms of solubility. The present invention also relates to a preparation method of the new crystalline form, pharmaceutical...
|
|
WO/2014/199295A1 |
The present invention provides the use of pyrazosulfuron ethyl for the control of winter weeds in winter crops that are not rice, and a composition useful therein.
|
|
WO/2014/199960A1 |
The present invention provides a novel compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive imp...
|
|
WO/2014/201172A1 |
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of G...
|
|
WO/2014/194848A1 |
Disclosed in the invention are the design, synthesis and activity study of a multi-targeted ubenimex prodrug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (where...
|
|
WO/2014/190804A1 |
The present invention relates to a new method for preparing crystal form F of erlotinib HCl. The method comprises adding an erlotinib free alkali in a C4 alcohol into hydrogen chloride dissolved in an organic solvent, and crystallizing t...
|
|
WO/2014/192903A1 |
The present invention addresses the problem of providing a novel form of an (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl
}{5-[2-(methylsulfonyl)ethoxy]pyrimidine-2-yl}amino)methyl]-
4-(trifluoromethyl)phenyl}(ethyl)amino)...
|
|
WO/2014/190997A1 |
Process for preparing 4,6-bis(aryloxy)pyrimidine derivatives A process is provided for preparing 4,6-bis(aryloxy)pyrimidine derivatives. The process is conducted in water as reaction medium and catalyzed by one or more tertiary-amine cat...
|
|
WO/2014/183502A1 |
Disclosed in the present invention is a preparation method of Azoxystrobin having a structure as shown by formula (1), the method comprising: a) performing an etherification reaction by reacting the compound having a structure shown by f...
|
|
WO/2014/185751A1 |
The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present invention, an organic electroluminescen...
|
|
WO/2014/181788A1 |
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...
|
|
WO/2014/182593A1 |
The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same. Examples include hydrobromide and bis-besylate salts of N-(3...
|
|
WO/2014/181287A1 |
The present invention provides heterocyclyl compounds of formula I, isotopic forms, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, solvates, N- oxides, S-oxides and polymorphs thereof, and processes for their p...
|
|
WO/2014/178389A1 |
Provided is a new compound having glycogen synthase activation potency, high muscular transition, minimal activation of receptor PPAR, and a high degree of safety. Provided is a compound represented by the following general formula, or a...
|
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
|
WO/2014/173029A1 |
A new nitrogen mustard derivative of Formula I or a pharmaceutically acceptable salt thereof, where R is N(CH2CH2Cl)2. Experiments show that the compound can inhibit a phase of the cell in Phase G2/M and is a dual-function alkylating age...
|
|
WO/2014/174307A1 |
The invention relates to new quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, ...
|
|
WO/2014/174601A1 |
The present invention relates to a pyrimidine derivative represented by formula (I). (In formula (I), R1, R2, R3, R4, R5, R6, and R7 are hydrogen or the like; X is a structure represented by formula (II) or formula (III), or is Y; and Y ...
|
|
WO/2014/170403A1 |
There is provided inter alia a compound of formula (I), Q-L-P wherein Q is a moiety that binds to the ATP -binding site of a Pim kinase; L is an organic tether that connects Q to P and permits simultaneous binding of Q and P to a Pim kin...
|
|
WO/2014/171541A1 |
The present invention provides a novel cyclic azine compound for an organic electroluminescence element having exceptional service life characteristics (substituent B individually indicates an azabenzene group, a diazabenzene group, or a...
|
|
WO/2014/170413A1 |
The present invention relates to a compound of formula (I): wherein the substituents are as defined herein, and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are t...
|
|
WO/2014/170792A1 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...
|
